C-Suite Roundtable: Navigating the Healthcare Capital Lifecycle from Seed to Post-Listing
Yesterday in Shanghai, more than 30 business leaders and investors from mainland China and Hong Kong gathered at a South China Morning Post C-Suite roundtable on “The Capital Lifecycle of the Healthcare Sector: From Seed to Post-Listing” held alongside BioShanghai Week 2026. The event, supported by IHH Healthcare North Asia, featured guest speakers Nisa Leung, founding managing partner of Aulis…
Investors and healthcare executives from mainland China and Hong Kong convened in Shanghai for a C-Suite roundtable organized by the South China Morning Post. The meeting, held during BioShanghai Week 2026, focused on the journey of healthcare capital from early-stage funding to post-listing commercialization. The event, backed by IHH Healthcare North Asia, featured Nisa Leung, Aulis Capital's founding managing partner, and Dr Kenneth Tsang, IHH Healthcare North Asia's regional CEO.
A key issue raised was the disparity between scientific advancements and the financial infrastructure necessary to support and commercialize them. The conversation compared China's expanding biotech landscape with the more robust funding environments and markets found in the US and Europe. The panel also explored strategies such as out-licensing, "NewCo" structures, and multi-regional clinical trials.
Hong Kong's significance was highlighted, with discussions surrounding the city's potential to serve as a testing ground for innovative healthcare solutions and the impact of takeover and delisting regulations on biotech exit strategies. The group recognized the potential benefits of enhanced cross-border data flows and coordinated clinical trials to bridge the gap between Chinese patients and international regulatory requirements.
The discussions occurred as Hong Kong unveiled its inaugural Five-Year Plan, aimed at transforming the city into a global hub for health and medical innovation. A notable challenge highlighted was the capital requirements for AI-driven drug discovery, where the combination of advanced computing and specialized talent was driving costs up.
The attendees debated the merits of strategic computing partnerships over extensive hardware investments and the importance of aligning research and development efforts with clinically validated needs. Overall, the roundtable provided a comprehensive overview of the healthcare capital lifecycle, mapping out the interconnections between funding, clinical validation, regulatory processes, commercialization, and international market access.
Written by urgent.news from SCMP Business's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
